Wave Life Sciences Receives a Buy from Mizuho Securities


Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences (NASDAQ: WVE) today and set a price target of $65. The company’s shares opened today at $35.20.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -1.1% and a 50.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Spark Therapeutics, and Aerie Pharma.

Wave Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $60, a 70.5% upside from current levels. In a report issued on June 20, Leerink Partners also reiterated a Buy rating on the stock with a $55 price target.

.

See today’s analyst top recommended stocks >>

Based on Wave Life Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.24 million. In comparison, last year the company had a GAAP net loss of $21 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Wave Life Sciences Ltd. operates as a preclinical biopharmaceutical company, which engages in the development and provision of nucleic acid therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.

Read More on WVE:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts